Instead, based on in vitro phenotypes and on potential drug response predicted by transcriptome profile, histone deacetylase inhibitors (HDACIs) including chidamide and a new suberanilohydroxamic acid (SAHA)–bendamustine hybrid NL-101 significantly prolonged the survival of TR mice, providing therapeutic value for improving APL patient outcome with rare RARα fusion genes. The gene discussed is RARA; the disease is acute promyelocytic leukemia.